A guidance document changes while a submission is being assembled. How do you assess the impact?

Why

Guidance is not binding in the US: FDA guidances describe current thinking, and an alternative approach is acceptable if it satisfies the statute and regulations. EMA scientific guidelines are similar in weight, and each states when it comes into effect. But reviewers read submissions against current guidance, so a gap needs a reason.

Start with what changed. A new final guidance replacing a draft carries more weight than a draft. A new effective date tells you whether your submission falls under it.

Then map the changes to your dossier. A change to the recommended content of a module, such as new expectations for a risk management plan, may only need text. A change to evidence, such as a new expectation for a comparator or endpoint, may be impossible to meet in completed trials and needs a written justification.

A technical change, such as a new data standard version required after a date, can block a submission outright, because some technical requirements are binding through other instruments. Record the assessment and decisions so the reasoning is visible later.